Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare autosomal recessive lysosomal storage disease.
  • This neurodegenerative disorder usually presents between ages 2 and 4 years with psychomotor decline, seizures, and vision loss which progress to a vegetative state and death in the 2nd decade of life (1).
  • Synonym(s): Jansky-Bielschowsky disease, late-infantile neuronal ceroid lipofuscinosis (NCL) and late-infantile Batten disease

Epidemiology

Incidence
  • Worldwide reported incidence estimates range from 0.22 to 9 per 100,000 live births (1).
  • In the United States, CLN2 occurs in an estimated 2 to 4 of every 100,000 live births.

Prevalence
CLN2 has an estimated prevalence of 0.6 to 0.7 per million inhabitants worldwide.

Etiology and Pathophysiology

  • CLN2 is caused by deficiency of the enzyme tripeptidyl peptidase 1 (TPP1), leading to the lysosomal accumulation of an autofluorescent lipopigment with subsequent neuronal degeneration of the hippocampus, cortical interneurons, cerebellum, and thalamocortical neurons (1,2).
  • TPP1 cleaves tripeptides from the N-terminus of diverse partially unfolded lysosomal proteins; however, the in vivo substrates of TPP1 are unknown.
  • The mechanism by which failure to cleave these N-terminal peptides leads to neuronal death and the clinical manifestations seen in CLN2 is poorly understood.

Genetics
  • This disorder is caused by mutations in the TPP1/CLN2 gene located in chromosome 11p15.4 (OMIM 204500).
  • The two most common mutations found in patients with CLN2 are c.509-1G>C, a splicing mutation, and, c.622C>T (R208X), which results in the introduction of a termination codon prematurely.

General Prevention

  • Prenatal diagnosis is an option in patients with family history of CLN2 or known carriers.
  • Genetic counseling should be offered to family members and the risk of CLN2 should be assessed for subsequent pregnancies.

Commonly Associated Conditions

  • Epilepsy is present in 75% of children with CLN2, usually diagnosed between age 2 and 4 years.
  • Perioperative hypothermia secondary to impaired thermoregulation in the setting of autonomic nerve dysfunction is common.
  • Cardiac conduction defects, tachyarrhythmias, and sudden cardiac death have been reported.

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease ID - 1688188 ED - Baldor,Robert A, ED - Domino,Frank J, ED - Golding,Jeremy, ED - Stephens,Mark B, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688188/all/Neuronal_Ceroid_Lipofuscinosis_Type_2__CLN2__Disease PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -